Cambridge Healthtech Institute’s 2nd Annual

Immunology and Oncology: Emerging Drug Targets and Therapeutics

New Approaches for Treating Autoimmunity and Cancer

September 16-17, 2020


The rapid pace of research in the immunology field and medically relevant signaling pathways highlighted by new biologics on the market are providing a plethora of new drug targets whose modulation are showing promise for treating diseases of the immune system or cancer. Often it’s the same target, modulated in opposite ways, that proves beneficial for both diseases. This conference covers such dual targets. We also focus on molecular targets whose modulation impacts either one or the other (autoimmunity or oncology). All drug modalities will be explored, though an emphasis will be on small molecules because many of the newest drug targets are intra-cellular.

Preliminary Agenda


Arginase Inhibitors for Combatting Cancer

Alwin Schuller, PhD, Senior Principal Scientist/Team Lead, Oncology, IMED, Biotech Unit, AstraZeneca

Targeting Metabolic Pathways in Immune Cells

Masha Poyurovsky, PhD, Vice President, Discovery Biology, Kadmon Corporation, LLC

Targeting Metabolic Susceptibilities in the Treatment of Hematologic Malignancies

Josh Murtie, PhD, Senior Director, Head of Cancer Biology, Agios

The Role of Aryl Hydrocarbon Receptor and the Kyneurin Pathway in Cancer Immuno-Metabolism

David Sherr, PhD, Professor, Pathology and Laboratory Medicine, Boston University

Small Molecules against the Adenosine Receptor as an Immuno-Oncology Strategy

Brandon Rosen, PhD, Senior Scientist, Chemistry, Arcus Biosciences

Updates on Non-Brain-Penetrant A2aR-Selective Antagonist That Maintains Potency in High Adenosine Tumor Microenvironment

Gregory Driessens, PhD, Project Leader, in vivo Pharmacology, iTeos Therapeutics


Regulation of Inflammatory Cell Death Signaling by RIP Kinases

Domagoj Vucic, PhD, Principal Scientist, Early Discovery Biology, Genentech

ROR-Gamma Inverse Agonist for the Treatment of Psoriasis

Murali Ramachandra, PhD, CEO, Aurigene Discovery Technologies Limited

A Novel Macrocycle-Bridged STING Agonist with Pan-Genotypic and Potent Antitumor Activity

Kuan-Chun Huang, PhD, Associate Director, Immuno-Oncology and Pharmacology, H3 Biomedicine

Presentation to be Announced

Presentation to be Announced

For more details on the conference, please contact:

Anjani Shah, PhD

Senior Conference Director

Cambridge Healthtech Institute

Phone: (+1) 781-247-6252



For partnering and sponsorship information, please contact:

Rod Eymael

Manager, Business Development

Cambridge Healthtech Institute

Phone: (+1) 781-247-6286